BioCryst director granted 644 shares at $9.70

Biocryst director Jon P. Stonehouse received a small stock grant in lieu of part of his quarterly cash board retainer.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. Stonehouse Jon P reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC (BCRX) director Jon P. Stonehouse received a grant of 644 shares of Common Stock on August 31, 2026, at a value of $9.70 per share. The shares were issued in lieu of 50% of a quarterly cash Board Member retainer of $12,500. Following this award, he holds 1,340,419 shares directly, plus 40,000 shares held indirectly in each of two irrevocable trusts for Caroline and Samuel Stonehouse. No Rule 10b5‑1 trading plan is reported.

Insider Trade Summary

Grant/Award: 644 shares

Grant/Award 3 txns

Insider Stonehouse Jon P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	644	$9.70	$6K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,340,419 shares (Direct); Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust); Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

Key Figures

Shares granted: 644 shares Grant value per share: $9.70 per share Quarterly Board Member retainer: $12,500 +3 more

6 metrics

Shares granted 644 shares Equity issued on August 31, 2026 in lieu of part of quarterly Board retainer

Grant value per share $9.70 per share Value used for the 644-share Common Stock grant on August 31, 2026

Quarterly Board Member retainer $12,500 Shares issued in lieu of 50% of this quarterly cash Board Member retainer

Direct holdings after grant 1,340,419 shares Jon P. Stonehouse direct Common Stock ownership after August 31, 2026 grant

Indirect holdings – Caroline trust 40,000 shares Common Stock held indirectly by wife as co‑trustee of the Caroline Stonehouse Irrevocable Trust

Indirect holdings – Samuel trust 40,000 shares Common Stock held indirectly by wife as co‑trustee of the Samuel Stonehouse Irrevocable Trust

Key Terms

Irrevocable Trust, co-trustee, quarterly cash Board Member retainer

3 terms

Irrevocable Trust financial

"By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

co-trustee financial

"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"

quarterly cash Board Member retainer financial

"in lieu of 50% of the quarterly cash Board Member retainer of $12,500"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BCRX director Jon P. Stonehouse report on this Form 4?

He reported a grant of 644 shares of Common Stock on August 31, 2026. The shares were issued in lieu of 50% of a $12,500 quarterly cash Board Member retainer, representing equity compensation rather than cash for part of his director fees.

At what value were the new BCRX shares granted to Jon P. Stonehouse?

The 644 Common Stock shares were valued at $9.70 per share on August 31, 2026. This equity grant was issued in lieu of 50% of a $12,500 quarterly cash Board Member retainer.

How many BCRX shares does Jon P. Stonehouse own after this transaction?

After the August 31, 2026 grant, Jon P. Stonehouse directly owns 1,340,419 shares of Biocryst Pharmaceuticals Common Stock. In addition, 40,000 shares are held indirectly in each of two irrevocable trusts where his wife is co‑trustee.

What indirect BCRX holdings are associated with Jon P. Stonehouse?

There are two indirect positions of 40,000 BCRX shares each, held by his wife as co‑trustee of the Caroline Stonehouse Irrevocable Trust and the Samuel Stonehouse Irrevocable Trust. These are reported as indirect beneficial ownership.

Was Jon P. Stonehouse’s BCRX transaction under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan; the document-level checkbox affirming trades under such a plan is not selected for these reported holdings and the 644-share grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:17 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stonehouse Jon P

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A		644(1)	A	$9.7	1,340,419	D
Common Stock								40,000	I	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock								40,000	I	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

	/s/ Alane P. Barnes, by power of attorney	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)